Correspondence 0001193125-22-295586 from Syros Pharmaceuticals, Inc. (SYRS) (CIK 0001556263)
Syros Pharmaceuticals, Inc. (SYRS) (CIK 0001556263)
Date: Nov. 30, 2022 · CIK: 0001556263 · Accession: 0001193125-22-295586
AI Filing Summary & Sentiment
File numbers found in text: 333-267888
Referenced dates: October 28, 2022
Letter
Cynthia T. Mazareas
+1 617 526 6393 (t)
+1 617 526 5000 (f)
cynthia.mazareas@wilmerhale.com
November 30, 2022
Via EDGAR Submission
Securities and Exchange Commission
Division of Corporation Finance – Office of Life Sciences
100 F Street, NE
Washington, DC 20549
Attention: Lauren Hamill
Tim Buchmiller
Re: Syros Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed October 14, 2022
File No. 333-267888
Ladies and Gentlemen:
On behalf of Syros Pharmaceuticals, Inc. (the “Company”), we are responding to the comment contained in the letter dated October 28, 2022 from the staff (the “Staff”) of the Securities and Exchange Commission to Gerald E. Quirk, Esq., the Company’s Chief Legal Officer, relating to the Registration Statement on Form S-3 referenced above (the “Registration Statement”). In response to the Staff’s comment, the Company has revised the Registration Statement and is submitting herewith for filing an Amendment No. 1 to the Registration Statement (the “Revised Registration Statement”) with this response letter.
The response set forth below is based upon information provided to Wilmer Cutler Pickering Hale and Dorr LLP by the Company. For convenience, the response is keyed to the numbering of the comment and the heading used in the Staff’s letter. Where appropriate, the Company has responded to the Staff’s comments by making changes to the disclosure in the Registration Statement as set forth in the Revised Registration Statement.
Securities and Exchange Commission
November 30, 2022
Page 2
On behalf of the Company, we advise you as follows:
General
1. We note that you filed a current report on Form 8-K on September 16, 2022 in connection with the completion of your acquisition of Tyme Technologies, Inc., and that this 8-K is incorporated by reference into your registration statement on Form S-3. You indicated in that Form 8-K that the financial statements of the acquired business and pro forma financial information required by Item 9.01(a) and (b) of Form 8-K would be filed by amendment within 71 days. Please note that we will not be a position to accelerate the effective date of this registration statement until you have filed the required financial statements and pro forma financial information. Refer to the Instruction to Item 9.01 of Form 8-K. It also appears that such incorporation by reference would require that an auditors’ consent be provided for the incorporation by reference into this registration statement of the auditor’s report with respect to the consolidated financial statements of Tyme Technologies, Inc. included in the Annual Report on Form 10-K for the year ended March 31, 2022 and that a consent should be filed for the incorporation by reference of such auditor’s report into any previously filed Securities Act registration statement. See the Exhibits Table in Item 601(a) of Regulation S-K and footnote 5 thereto. Please revise your filings or advise, as appropriate.
Response: The Company has filed the required financial statements and pro forma financial information for the acquisition of Tyme Technologies, Inc. (“Tyme Technologies”) by amendment to the original Current Report on Form 8-K (the “Amended 8-K”) on November 30, 2022 (which is within 71 calendar days after the date the original Current Report on Form 8-K was required to be filed). The Amended 8-K is incorporated by reference into the Revised Registration Statement pursuant to the terms thereof. The Company has also filed an auditors’ consent as an exhibit to the Revised Registration Statement for the incorporation by reference into the Revised Registration Statement of the auditor’s report with respect to the consolidated financial statements of Tyme Technologies included in its Annual Report on Form 10-K for the year ended March 31, 2022.
* * *
Securities and Exchange Commission
November 30, 2022
Page 3
If you have any further questions or comments, or if you require any additional information, please contact the undersigned by telephone at (617) 526-6393. Thank you for your assistance.
Very truly yours,
/s/ Cynthia T. Mazareas
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
Cynthia T. Mazareas
+1 617 526 6393 (t)
+1 617 526 5000
(f)
cynthia.mazareas@wilmerhale.com
November 30, 2022
Via EDGAR Submission
Securities and Exchange Commission
Division of Corporation
Finance – Office of Life Sciences
100 F Street, NE
Washington, DC 20549
Attention:
Lauren Hamill
Tim Buchmiller
Re:
Syros Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed October 14, 2022
File No. 333-267888
Ladies and Gentlemen:
On behalf of Syros Pharmaceuticals, Inc.
(the “Company”), we are responding to the comment contained in the letter dated October 28, 2022 from the staff (the “Staff”) of the Securities and Exchange Commission to Gerald E. Quirk, Esq., the Company’s Chief Legal
Officer, relating to the Registration Statement on Form S-3 referenced above (the “Registration Statement”). In response to the Staff’s comment, the Company has revised the Registration
Statement and is submitting herewith for filing an Amendment No. 1 to the Registration Statement (the “Revised Registration Statement”) with this response letter.
The response set forth below is based upon information provided to Wilmer Cutler Pickering Hale and Dorr LLP by the Company. For convenience, the response is
keyed to the numbering of the comment and the heading used in the Staff’s letter. Where appropriate, the Company has responded to the Staff’s comments by making changes to the disclosure in the Registration Statement as set forth in the
Revised Registration Statement.
Securities and Exchange Commission
November 30, 2022
Page 2
On behalf of the Company, we advise you as follows:
General
1.
We note that you filed a current report on Form 8-K on
September 16, 2022 in connection with the completion of your acquisition of Tyme Technologies, Inc., and that this 8-K is incorporated by reference into your registration statement on Form S-3. You indicated in that Form 8-K that the financial statements of the acquired business and pro forma financial information required by Item 9.01(a) and (b) of Form 8-K would be filed by amendment within 71 days. Please note that we will not be a position to accelerate the effective date of this registration statement until you have filed the required financial statements and
pro forma financial information. Refer to the Instruction to Item 9.01 of Form 8-K. It also appears that such incorporation by reference would require that an auditors’ consent be provided for the
incorporation by reference into this registration statement of the auditor’s report with respect to the consolidated financial statements of Tyme Technologies, Inc. included in the Annual Report on Form
10-K for the year ended March 31, 2022 and that a consent should be filed for the incorporation by reference of such auditor’s report into any previously filed Securities Act registration statement.
See the Exhibits Table in Item 601(a) of Regulation S-K and footnote 5 thereto. Please revise your filings or advise, as appropriate.
Response: The Company has filed the required financial statements and pro forma financial information for the acquisition of Tyme
Technologies, Inc. (“Tyme Technologies”) by amendment to the original Current Report on Form 8-K (the “Amended 8-K”) on November 30, 2022 (which
is within 71 calendar days after the date the original Current Report on Form 8-K was required to be filed). The Amended 8-K is incorporated by reference into the
Revised Registration Statement pursuant to the terms thereof. The Company has also filed an auditors’ consent as an exhibit to the Revised Registration Statement for the incorporation by reference into the Revised Registration Statement of the
auditor’s report with respect to the consolidated financial statements of Tyme Technologies included in its Annual Report on Form 10-K for the year ended March 31, 2022.
* * *
Securities and Exchange Commission
November 30, 2022
Page 3
If you have any further questions or comments, or if you require any additional information, please contact
the undersigned by telephone at (617) 526-6393. Thank you for your assistance.
Very truly yours,
/s/ Cynthia T. Mazareas
Cynthia T. Mazareas
cc:
Gerald E. Quirk, Esq., Syros Pharmaceuticals, Inc.
Todd Rosenthal, Esq., Syros Pharmaceuticals, Inc.
Nancy Simonian, M.D., Syros Pharmaceuticals, Inc.